Apyx Medical Appoints Stavros Vizirgianakis as Executive Chairman, Grants $1.9M in RSUs
APYX has more than doubled off its 52-week low of $1.59.
Summary
Apyx Medical appointed its Chairman, Stavros Vizirgianakis, as Executive Chairman and granted him 450,000 Restricted Stock Units (RSUs) valued at approximately $1.9 million, with immediate and staggered vesting.
Key Events · Executive and Board Changes · APYX
-
Executive Chairman Appointed
Stavros Vizirgianakis, current Chairman of the Board, has been appointed Executive Chairman, taking on a more active role in strategic leadership, governance, and capital markets.
-
Significant RSU Grant
Mr. Vizirgianakis received a grant of 450,000 Restricted Stock Units (RSUs), valued at approximately $1.9 million based on the current stock price.
-
Vesting Schedule
150,000 RSUs vested immediately on June 11, 2026, with the remaining 300,000 RSUs vesting ratably over the next two years, subject to continued service.
Analysis · APYX · Industrial Applications And Services
Apyx Medical has appointed its current Chairman, Stavros Vizirgianakis, to the newly created role of Executive Chairman. This move aims to strengthen strategic leadership, enhance governance, and support capital market initiatives. In connection with this, Mr. Vizirgianakis received a substantial grant of 450,000 Restricted Stock Units (RSUs), valued at approximately $1.9 million based on the current stock price. While dilutive, this compensation package, which includes immediate vesting of 150,000 RSUs, aligns his interests with the company's long-term performance and comes after a period of positive regulatory and financial news for Apyx Medical.
At the time of this filing, APYX was trading at $4.21 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $176.3M. The 52-week trading range was $1.59 to $5.08. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.